Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 746

1.

Impact of cardiology follow-up care on treatment and outcomes of patients with new atrial fibrillation discharged from the emergency department.

Hawkins NM, Scheuermeyer FX, Youngson E, Sandhu RK, Ezekowitz JA, Kaul P, McAlister FA.

Europace. 2019 Dec 4. pii: euz302. doi: 10.1093/europace/euz302. [Epub ahead of print]

PMID:
31800033
2.

Heart failure treatment and the art of medical decision making.

McAlister FA, Ezekowitz JA, Armstrong PW.

Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1655. [Epub ahead of print] No abstract available.

PMID:
31769152
3.

Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.

Sharma A, Wu J, Ezekowitz JA, Felker GM, Udell JA, Heidenreich PA, Fonarow GC, Mahaffey KW, Hernandez AF, DeVore AD.

ESC Heart Fail. 2019 Nov 20. doi: 10.1002/ehf2.12528. [Epub ahead of print]

4.

Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.

Cherney DZ, Odutayo A, Aronson R, Ezekowitz J, Parker JD.

J Am Coll Cardiol. 2019 Nov 19;74(20):2511-2524. doi: 10.1016/j.jacc.2019.09.022. Review.

PMID:
31727290
5.

Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.

Loring Z, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Mahaffey KW, Naccarelli GV, Pieper K, Reiffel JA, Singer DE, Steinberg BA, Thomas LE, Peterson ED, Piccini JP.

Am Heart J. 2019 Nov 8;219:21-30. doi: 10.1016/j.ahj.2019.10.008. [Epub ahead of print]

PMID:
31710841
6.

All for one, but not one for all.

Ezekowitz JA.

Eur Heart J. 2019 Nov 9. pii: ehz808. doi: 10.1093/eurheartj/ehz808. [Epub ahead of print] No abstract available.

PMID:
31710659
7.

Screening and Initiating Supportive Care in Patients With Heart Failure.

Nguyen Q, Wang K, Nikhanj A, Chen-Song D, DeKock I, Ezekowitz J, Mirhosseini M, Cujec B, Oudit GY.

Front Cardiovasc Med. 2019 Oct 22;6:151. doi: 10.3389/fcvm.2019.00151. eCollection 2019.

8.

The hospital frailty risk score in patients with heart failure is strongly associated with outcomes but less so with pharmacotherapy.

McAlister FA, Savu A, Ezekowitz JA, Armstrong PW, Kaul P.

J Intern Med. 2019 Oct 29. doi: 10.1111/joim.13002. [Epub ahead of print]

PMID:
31661589
9.

Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial.

Rachwan RJ, Butler J, Collins SP, Cotter G, Davison BA, Senger S, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, de Boer RA, Soergel DG, Felker GM, Pang PS.

Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1607. [Epub ahead of print]

PMID:
31646707
10.

Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure.

Sharma A, Ezekowitz JA.

Can J Diabetes. 2019 Aug 23. pii: S1499-2671(19)30616-1. doi: 10.1016/j.jcjd.2019.08.012. [Epub ahead of print] Review.

PMID:
31630988
11.

2017 Guidelines for the management of heart failure by pharmacists.

Beique LC, Ezekowitz JA, O'Meara E, McDonald M, Koshman SL.

Can Pharm J (Ott). 2019 Jul 2;152(5):301-316. doi: 10.1177/1715163519853307. eCollection 2019 Sep-Oct. No abstract available.

12.

Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging.

Thompson RB, Chow K, Pagano JJ, Sekowski V, Michelakis ED, Tymchak W, Haykowsky MJ, Ezekowitz JA, Oudit GY, Dyck JRB, Kaul P, Savu A, Paterson DI.

J Cardiovasc Magn Reson. 2019 Sep 12;21(1):58. doi: 10.1186/s12968-019-0567-y.

13.

Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades.

Sepehrvand N, Alemayehu W, Das D, Gupta AK, Gouda P, Ghimire A, Du AX, Hatami S, Babadagli HE, Verma S, Kashour Z, Ezekowitz JA.

JAMA Cardiol. 2019 Sep 1. doi: 10.1001/jamacardio.2019.3604. [Epub ahead of print]

PMID:
31473763
14.

Empirical Insights When Defining the Population Burden of Atrial Fibrillation and Oral Anticoagulation Utilization Using Administrative Data.

Hawkins NM, Daniele PR, Humphries KH, Ezekowitz JA, McAlister FA, Sandhu RK, Kaul P.

Can J Cardiol. 2019 Oct;35(10):1412-1415. doi: 10.1016/j.cjca.2019.05.009. Epub 2019 May 15.

PMID:
31473069
15.

Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.

Januzzi JL Jr, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Mark DB, Piña IL, Passmore G, Whellan DJ, Cooper LS, Leifer ES, Desvigne-Nickens P, Felker GM, O'Connor CM.

J Am Coll Cardiol. 2019 Sep 3;74(9):1205-1217. doi: 10.1016/j.jacc.2019.06.055.

PMID:
31466618
16.

Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.

Merino JL, Lip GYH, Heidbuchel H, Cohen AA, De Caterina R, de Groot JR, Ezekowitz MD, Le Heuzey JY, Themistoclakis S, Jin J, Melino M, Winters SM, Merkely B, Goette A.

Europace. 2019 Nov 1;21(11):1633-1638. doi: 10.1093/europace/euz213.

17.

Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study.

Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA.

Eur Heart J. 2019 Jul 1;40(26):2110-2117. doi: 10.1093/eurheartj/ehz233.

PMID:
31280320
18.

Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.

Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, Singer DE, Freeman JV, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli GV, Ezekowitz MD, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators.

JAMA Cardiol. 2019 Jul 3. doi: 10.1001/jamacardio.2019.1960. [Epub ahead of print]

19.

Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.

Inohara T, Shrader P, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Go AS, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP; ORBIT AF Patients and Investigators.

Am Heart J. 2019 Jul;213:81-90. doi: 10.1016/j.ahj.2019.04.007. Epub 2019 Apr 24.

PMID:
31129441
20.

High vs. low oxygen therapy in patients with acute heart failure: HiLo-HF pilot trial.

Sepehrvand N, Alemayehu W, Rowe BH, McAlister FA, van Diepen S, Stickland M, Ezekowitz JA.

ESC Heart Fail. 2019 Aug;6(4):667-677. doi: 10.1002/ehf2.12448. Epub 2019 May 17.

21.

Rationale and Design of the VITALITY-HFpEF Trial.

Butler J, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, Wu Y, Carvalho F, Bamber L, Blaustein RO, Roessig L, Armstrong PW.

Circ Heart Fail. 2019 May;12(5):e005998. doi: 10.1161/CIRCHEARTFAILURE.119.005998.

PMID:
31096775
22.

Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score.

Holmes DN, Piccini JP, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, O'Brien EC, Reiffel JA, Naccarelli GV, Ezekowitz MD, Chan PS, Singer DE, Spertus JA, Peterson ED, Thomas L.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005358. doi: 10.1161/CIRCOUTCOMES.118.005358.

PMID:
31092022
23.

External Validation of the H2F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction.

Sepehrvand N, Alemayehu W, Dyck GJB, Dyck JRB, Anderson T, Howlett J, Paterson I, McAlister FA, Ezekowitz JA.

Circulation. 2019 May 14;139(20):2377-2379. doi: 10.1161/CIRCULATIONAHA.118.038594. No abstract available.

PMID:
31082301
24.

Incremental costs of high intensive care utilisation in patients hospitalised with heart failure.

van Diepen S, Tran DT, Ezekowitz JA, Schnell G, Wiley BM, Morrow DA, McAlister FA, Kaul P.

Eur Heart J Acute Cardiovasc Care. 2019 Oct;8(7):660-666. doi: 10.1177/2048872619845282. Epub 2019 Apr 12.

PMID:
30977391
25.

Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.

O'Connor C, Fiuzat M, Mulder H, Coles A, Ahmad T, Ezekowitz JA, Adams KF, Piña IL, Anstrom KJ, Cooper LS, Mark DB, Whellan DJ, Januzzi JL Jr, Leifer ES, Felker GM.

Eur J Heart Fail. 2019 Jun;21(6):770-778. doi: 10.1002/ejhf.1450. Epub 2019 Mar 27.

PMID:
30919549
26.

The Relationship Between Heart-Failure Hospitalization and Mortality in Patients Receiving Transcatheter Aortic Valve Replacement.

Nazzari H, Hawkins NM, Ezekowitz J, Lauck S, Ding L, Polderman J, Yu M, Boone RH, Cheung A, Ye J, Wood D, Webb J, Toma M.

Can J Cardiol. 2019 Apr;35(4):413-421. doi: 10.1016/j.cjca.2018.11.016. Epub 2018 Nov 28.

PMID:
30853134
27.

Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients.

Li D, Weinkauf J, Hirji A, Kapasi A, Lien D, Nagendran J, Kim D, Ezekowitz J, Halloran K.

J Heart Lung Transplant. 2019 Jul;38(7):710-718. doi: 10.1016/j.healun.2019.02.010. Epub 2019 Feb 18.

PMID:
30850154
28.

Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.

Alak A, Hohnloser SH, Fräßdorf M, Reilly P, Ezekowitz M, Healey JS, Brueckmann M, Yusuf S, Connolly SJ.

Europace. 2019 Jul 1;21(7):1023-1030. doi: 10.1093/europace/euz021.

PMID:
30848783
29.

Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry).

Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Chang P, Fonarow GC, Ezekowitz MD, Hylek E, Go AS, Kowey PR, Mahaffey KW, Gersh BJ, Peterson ED.

Am J Cardiol. 2019 May 15;123(10):1628-1636. doi: 10.1016/j.amjcard.2019.02.010. Epub 2019 Feb 23.

PMID:
30846214
30.

The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review.

Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA.

Int J Mol Sci. 2019 Feb 19;20(4). pii: E904. doi: 10.3390/ijms20040904. Review.

31.

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.

Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD.

Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.

PMID:
30773022
32.

Creating order out of chaos: quality of care in heart failure.

Ezekowitz JA.

Heart. 2019 Mar;105(6):429-430. doi: 10.1136/heartjnl-2018-314526. Epub 2019 Jan 31. No abstract available.

PMID:
30705055
33.

2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Writing Group Members, January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW.

Heart Rhythm. 2019 Aug;16(8):e66-e93. doi: 10.1016/j.hrthm.2019.01.024. Epub 2019 Jan 28. No abstract available.

PMID:
30703530
34.

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW.

J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. doi: 10.1016/j.jacc.2019.01.011. Epub 2019 Jan 28. No abstract available. Erratum in: J Am Coll Cardiol. 2019 Jul 30;74(4):599.

PMID:
30703431
35.

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW.

Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28. No abstract available.

PMID:
30686041
36.

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.

Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L.

J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.

37.

NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.

Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, Norris C, Cooper L, Leifer E, Desvigne-Nickens P, Anstrom K, Fiuzat M, Ezekowitz J, Mark DB, O'Connor CM, Januzzi J, Felker GM.

JACC Heart Fail. 2019 Feb;7(2):158-168. doi: 10.1016/j.jchf.2018.10.014. Epub 2019 Jan 2.

PMID:
30611722
38.

Update on the diagnosis and management of acute heart failure.

Gouda P, Ezekowitz JA.

Curr Opin Cardiol. 2019 Mar;34(2):202-206. doi: 10.1097/HCO.0000000000000594.

PMID:
30547895
39.

Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.

Du AX, Westerhout CM, McAlister FA, Shanks M, Oudit GY, Paterson DI, Hanninen M, Thomas J, Ezekowitz JA.

J Cardiovasc Pharmacol. 2019 Mar;73(3):149-154. doi: 10.1097/FJC.0000000000000643.

PMID:
30540684
40.

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.

Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L.

Open Heart. 2018 Nov 1;5(2):e000908. doi: 10.1136/openhrt-2018-000908. eCollection 2018.

41.

Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure.

Mark DB, Cowper PA, Anstrom KJ, Sheng S, Daniels MR, Knight JD, Baloch KN, Davidson-Ray L, Fiuzat M, Januzzi JL Jr, Whellan DJ, Piña IL, Ezekowitz JA, Adams KF, Cooper LS, O'Connor CM, Felker GM.

J Am Coll Cardiol. 2018 Nov 27;72(21):2551-2562. doi: 10.1016/j.jacc.2018.08.2184.

42.

Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging.

Alherbish A, Becher H, Alemayehu W, Paterson DI, Butler CR, Anderson TJ, Ezekowitz JA, Shanks M; Alberta HEART investigators.

Echocardiography. 2018 Nov;35(11):1746-1754. doi: 10.1111/echo.14152. Epub 2018 Oct 30.

PMID:
30376596
43.

Comparison of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial.

van Diepen S, Norris CM, Zheng Y, Nagendran J, Graham MM, Gaete Ortega D, Townsend DR, Ezekowitz JA, Bagshaw SM.

J Am Heart Assoc. 2018 Oct 16;7(20):e009917. doi: 10.1161/JAHA.118.009917.

44.

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Greene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.

45.

Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators.

Clapper JR, Henry CL, Niphakis MJ, Knize AM, Coppola AR, Simon GM, Ngo N, Herbst RA, Herbst DM, Reed AW, Cisar JS, Weber OD, Viader A, Alexander JP, Cunningham ML, Jones TK, Fraser IP, Grice CA, Ezekowitz RAB, O'Neill GP, Blankman JL.

J Pharmacol Exp Ther. 2018 Dec;367(3):494-508. doi: 10.1124/jpet.118.252296. Epub 2018 Oct 10.

PMID:
30305428
46.

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.

Tobe SW, Stone JA, Anderson T, Bacon S, Cheng AYY, Daskalopoulou SS, Ezekowitz JA, Gregoire JC, Gubitz G, Jain R, Keshavjee K, Lindsay P, L'Abbe M, Lau DCW, Leiter LA, O'Meara E, Pearson GJ, Rabi DM, Sherifali D, Selby P, Tu JV, Wharton S, Walker KM, Hua-Stewart D, Liu PP.

CMAJ. 2018 Oct 9;190(40):E1192-E1206. doi: 10.1503/cmaj.180194. No abstract available.

47.

Acute Coronary Syndromes and Heart Failure Critical Care Units Utilization and Outcomes in Teaching and Community Hospitals: A National Population-Based Analysis.

Verma S, Kaul P, Lin M, Ezekowitz JA, Zygun DA, Fordyce CB, Wang TY, McAlister FA, van Diepen S.

Can J Cardiol. 2018 Oct;34(10):1365-1368. doi: 10.1016/j.cjca.2018.07.419. Epub 2018 Jul 29.

PMID:
30269834
48.

B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation.

Inohara T, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP; ORBIT AF Patients and Investigators.

Heart. 2019 Mar;105(5):370-377. doi: 10.1136/heartjnl-2018-313642. Epub 2018 Sep 18.

PMID:
30228248
49.

Oxygen therapy in acute myocardial infarctions: do we need to re-evaluate its necessity?

Sepehrvand N, Ezekowitz JA.

Expert Rev Cardiovasc Ther. 2018 Oct;16(10):693-694. doi: 10.1080/14779072.2018.1523719. Epub 2018 Sep 19. No abstract available.

PMID:
30207191
50.

Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF).

Colin-Ramirez E, Ezekowitz JA; SODIUM-HF investigators.

Am Heart J. 2018 Nov;205:87-96. doi: 10.1016/j.ahj.2018.08.005. Epub 2018 Aug 16.

PMID:
30205241

Supplemental Content

Support Center